T. Rowe Price Associates
AVIR icon

T. Rowe Price Associates’s Atea Pharmaceuticals AVIR Stock Holding History

T. Rowe Price Associates’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$574K Buy
106,562
+9,242
+9% +$42.4K ﹤0.01% 2387
2025
Q4 		$348K Sell
97,320
-213
-0.2% -$677 ﹤0.01% 2567
2025
Q3 		$283K Buy
97,533
+17,623
+22% +$60.2K ﹤0.01% 2627
2025
Q2 		$288K Hold
79,910
– – ﹤0.01% 2549
2025
Q1 		$239K Buy
79,910
+6,027
+8% +$18.8K ﹤0.01% 2559
2024
Q4 		$248K Buy
73,883
+3,882
+6% +$12.9K ﹤0.01% 2596
2024
Q3 		$235K Buy
70,001
+3,341
+5% +$12.1K ﹤0.01% 2589
2024
Q2 		$221K Sell
66,660
-477
-0.7% -$1.78K ﹤0.01% 2555
2024
Q1 		$272K Buy
67,137
+11,968
+22% +$46.8K ﹤0.01% 2477
2023
Q4 		$169K Buy
55,169
+12,927
+31% +$39.1K ﹤0.01% 2599
2023
Q3 		$127K Buy
42,242
+1,010
+2% +$3.44K ﹤0.01% 2618
2023
Q2 		$155K Buy
41,232
+1,488
+4% +$5.57K ﹤0.01% 2596
2023
Q1 		$134K Buy
39,744
+10,931
+38% +$44.3K ﹤0.01% 2624
2022
Q4 		$139K Buy
28,813
+1,192
+4% +$6.03K ﹤0.01% 2641
2022
Q3 		$158K Buy
27,621
+4,540
+20% +$34.8K ﹤0.01% 2616
2022
Q2 		$164K Sell
23,081
-422,879
-95% -$2.89M ﹤0.01% 2649
2022
Q1 		$3.22M Buy
445,960
+33,045
+8% +$224K ﹤0.01% 1558
2021
Q4 		$3.69M Sell
412,915
-1,083,050
-72% -$16.9M ﹤0.01% 1543
2021
Q3 		$52.4M Sell
1,495,965
-195,517
-12% -$5.42M ﹤0.01% 989
2021
Q2 		$36.3M Sell
1,691,482
-869,893
-34% -$26.1M ﹤0.01% 1137
2021
Q1 		$154M Buy
2,561,375
+43,398
+2% +$2.93M 0.02% 635
2020
Q4 		$102M Buy
+2,517,977
New +$81.2M 0.01% 721

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

T. Rowe Price Associates's AVIR Position: Q1 2026 in Review

T. Rowe Price Associates increased its Atea Pharmaceuticals (AVIR) stake by 9.5% in Q1 2026, buying an estimated $42.4K and bringing the position to 106,562 shares worth $574K. The position accounts for ﹤0.01% of the portfolio, ranked #2387.

T. Rowe Price Associates first reported a position in AVIR in Q4 2020 and has held it in 22 quarters since. The position peaked at $154M in Q1 2021. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • T. Rowe Price Associates held 106,562 shares of Atea Pharmaceuticals worth $574K as of Q1 2026.
  • T. Rowe Price Associates bought 9,242 Atea Pharmaceuticals shares in Q1 2026, an estimated $42.4K.
  • Atea Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2387 holding.
  • T. Rowe Price Associates first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • T. Rowe Price Associates's Atea Pharmaceuticals position peaked at $154M in Q1 2021.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.